(3aR,4S,7R,7aS)-Hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione

We are (3aR,4S,7R,7aS)-Hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione CAS:14805-29-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(3aR,4S,7R,7aS)-Hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione
CAS.NO:14805-29-9
Synonyms:(3aR,4S,7R,7aS)-rel-hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione
(1R,2S,6R,7S)-4-Azatricyclo[5.2.1.0]decane-3,5-dione
(3aR,4S,7R,7aS) 4,7-Methano-1H-isoindole-1,3(2H)-dione
Molecular Formula:C9H11NO2
Molecular Weight:165.18900
 
Physical and Chemical Properties:
Density:1.4805
Melting point:148-158ºC
Boiling point:519.7ºC
Flash point:262.1ºC
 
Specification:
Appearance:White to off-white crystalline powder
Assay:≥98.0%
Loss on drying:≤0.5%
Endo isomerism:≤0.5%
Melting point:148-158ºC
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediates of Lurasidone
 
Note:The product under valid patents will not be offered to the countries covered by patents.

(3aR,4S,7R,7aS)-Hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione


Related News: In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.4-Amino-3,5-dichloropyridine In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid CAS:1012341-50-2 In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.50824-05-0 It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.

Related Products
Product Name
ALL-TRANS-RETINAL Cas:116-31-4 View Details
(2S,5R)-5-(benzyloxyamino)-piperidine-2-carboxylic acid amide View Details
4-(4-Fluorophenyl)-2-cyclopropylquinoline-3-carboxylic Acid Methyl Ester View Details
4-Amino-2-chloro-6-(trifluoromethyl)pyridine manufacturer Glycine manufacturer Sodium 2-(3,3-bis(4-(dimethylamino)phenyl)ureido)acetate Cas:115871-19-7 manufacturer benzyl 2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carboxylate,hydrochloride manufacturer 4-Nitroisoindolin-1-one manufacturer